P53+/- hemizygous knockout mouse: overview of available data. 2001

R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
Merck & Co Inc, West Point, Pennsylvania 19486, USA. richard_storer@merck.com

The performance of the p53-/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17beta-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-deficient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009153 Mutagens Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Clastogen,Clastogens,Genotoxin,Genotoxins,Mutagen
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes

Related Publications

R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2001, Toxicologic pathology,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2001, Toxicologic pathology,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2001, Toxicologic pathology,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2001, Toxicologic pathology,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 1995, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2019, EFSA journal. European Food Safety Authority,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
December 2015, Journal of applied toxicology : JAT,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
January 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
December 1995, Biochemical and biophysical research communications,
R D Storer, and J E French, and J Haseman, and G Hajian, and E K LeGrand, and G G Long, and L A Mixson, and R Ochoa, and J E Sagartz, and K A Soper
March 2003, Toxicology,
Copied contents to your clipboard!